|
1
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fucito A, Lucchetti C, Giordano A and
Romano G: Genetic and epigenetic alterations in breast cancer: What
are the perspectives for clinical practice? Int J Biochem Cell
Biol. 40:565–575. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Wezel T, Lombaerts M, van Roon EH,
Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ and Cleton-Jansen
AM: Expression analysis of candidate breast tumour suppressor genes
on chromosome 16q. Breast Cancer Res. 7:R998–R1004. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bagchi A and Mills AA: The quest for the
1p36 tumor suppressor. Cancer Res. 68:2551–2556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bièche I, Champème MH, Matifas F, Cropp
CS, Callahan R and Lidereau R: Two distinct regions involved in 1p
deletion in human primary breast cancer. Cancer Res. 53:1990–1994.
1993.PubMed/NCBI
|
|
6
|
Praml C, Finke LH, Herfarth C, Schlag P,
Schwab M and Amler L: Deletion mapping defines different regions in
1p34.2-pter that may harbor genetic information related to human
colorectal cancer. Oncogene. 11:1357–1362. 1995.PubMed/NCBI
|
|
7
|
Costello JF, Frühwald MC, Smiraglia DJ,
Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P,
Lang JC, et al: Aberrant CpG-island methylation has non-random and
tumor-type-specific patterns. Nat Genet. 24:132–138. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bagchi A, Papazoglu C, Wu Y, Capurso D,
Brodt M, Francis D, Bredel M, Vogel H and Mills AA: CHD5 is a tumor
suppressor at human 1p36. Cell. 128:459–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kolla V, Zhuang T, Higashi M, Naraparaju K
and Brodeur GM: Role of CHD5 in human cancers: 10 years later.
Cancer Res. 74:652–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mulero-Navarro S and Esteller M: Chromatin
remodeling factor CHD5 is silenced by promoter CpG island
hypermethylation in human cancer. Epigenetics. 3:210–215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clark SJ and Melki J: DNA methylation and
gene silencing in cancer: Which is the guilty party? Oncogene.
21:5380–5387. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Das PM and Singal R: DNA methylation and
cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holliday R: The inheritance of epigenetic
defects. Science. 238:163–170. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mokarram P, Kumar K, Brim H,
Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E,
Smoot DT and Ashktorab H: Distinct high-profile methylated genes in
colorectal cancer. PLoS One. 4:e70122009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Veronesi U, Viale G, Rotmensz N and
Goldhirsch A: Rethinking TNM: Breast cancer TNM classification for
treatment decision-making and research. Breast. 15:3–8. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zou B, Chim CS, Zeng H, Leung SY, Yang Y,
Tu SP, Lin MC, Wang J, He H, Jiang SH, et al: Correlation between
the single-site CpG methylation and expression silencing of the
XAF1 gene in human gastric and colon cancers. Gastroenterology.
131:1835–1843. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujita T, Igarashi J, Okawa ER, Gotoh T,
Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, et al: CHD5,
a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J
Natl Cancer Inst. 100:940–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Lau KK, So LK and Lam YW: CHD5 is
down-regulated through promoter hypermethylation in gastric cancer.
J Biomed Sci. 16:952009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fatemi M, Paul TA, Brodeur GM, Shokrani B,
Brim H and Ashktorab H: Epigenetic silencing of CHD5, a novel
tumor-suppressor gene, occurs in early colorectal cancer stages.
Cancer. 120:172–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gorringe KL, Choong DY, Williams LH,
Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL and Campbell IG:
Mutation and methylation analysis of the chromodomain-helicase-DNA
binding 5 gene in ovarian cancer. Neoplasia. 10:1253–1258. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao R, Yan Q, Lv J, Huang H, Zheng W,
Zhang B and Ma W: CHD5, a tumor suppressor that is epigenetically
silenced in lung cancer. Lung Cancer. 76:324–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koyama H, Zhuang T, Light JE, Kolla V,
Higashi M, McGrady PW, London WB and Brodeur GM: Mechanisms of CHD5
Inactivation in neuroblastomas. Clin Cancer Res. 18:1588–1597.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rinner B, Gallè B, Trajanoski S, Fischer
C, Hatz M, Maierhofer T, Michelitsch G, Moinfar F, Stelzer I,
Pfragner R and Guelly C: Molecular evidence for the bi-clonal
origin of neuroendocrine tumor derived metastases. BMC Genomics.
13:5942012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Futscher BW: Epigenetic changes during
cell transformation. Adv Exp Med Biol. 754:179–194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferguson NL, Bell J, Heidel R, Lee S,
Vanmeter S, Duncan L, Munsey B, Panella T and Orucevic A:
Prognostic value of breast cancer subtypes, Ki-67 proliferation
index, age, and pathologic tumor characteristics on breast cancer
survival in Caucasian women. Breast J. 19:22–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bardou VJ, Arpino G, Elledge RM, Osborne
CK and Clark GM: Progesterone receptor status significantly
improves outcome prediction over estrogen receptor status alone for
adjuvant endocrine therapy in two large breast cancer databases. J
Clin Oncol. 21:1973–1979. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan L, Yang X and Davidson NE: Role of DNA
methylation and histone acetylation in steroid receptor expression
in breast cancer. J Mammary Gland Biol Neoplasia. 6:183–192. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X, Ferguson AT, Nass SJ, Phillips DL,
Butash KA, Wang SM, Herman JG and Davidson NE: Transcriptional
activation of estrogen receptor alpha in human breast cancer cells
by histone deacetylase inhibition. Cancer Res. 60:6890–6894.
2000.PubMed/NCBI
|
|
31
|
Wu X, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang
Z, Luo A, Sun X, Fu L and Dong JT: Chromodomain helicase DNA
binding protein 5 plays a tumor suppressor role in human breast
cancer. Breast Cancer Res. 14:R732012. View
Article : Google Scholar : PubMed/NCBI
|
